Elicio Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Elicio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 3.06K shares, a 75.53% decline year-over-year.
- Elicio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 20.43K shares, a 1154.98% increase year-over-year.
- Elicio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 597.00 shares, a 41.07% decline year-over-year.
- Elicio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 17.79K shares, a 232.36% increase year-over-year.
- Elicio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 32.52K shares, a 233.25% increase from fiscal 2024.
- Elicio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 9.76K shares, a 40.32% decline from fiscal 2023.
- Elicio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 16.35K shares.
- Elicio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 152.94K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 3.06K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 41.88K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 20.43K shares 10-Q · filed 2026-05-11 | 51.32K shares derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | 597.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 32.52K shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 17.79K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 32.93K shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | 12.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 20.49K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 1.63K shares 10-Q · filed 2025-05-13 | 11.38K shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 1.01K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 9.76K shares 10-K · filed 2025-03-31 |
| 2024-09-30 | 5.35K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -36.70K shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 3.39K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -15.97K shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-15 | |
| 2023-12-31 | -45.44K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | 16.35K shares 10-K · filed 2024-03-29 |
| 2023-09-30 | 26.08K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | |
| 2022-03-31 | 0.00 shares 10-Q · filed 2022-05-16 | 152.78K shares derived: sum of 4 quarters · filed 2022-05-16 |
| 2021-12-31 | 17.76K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | 152.94K shares 10-K · filed 2022-03-30 |
| 2021-09-30 | 126.53K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | |
| 2021-06-30 | 8.49K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | |
| 2021-03-31 | 155.00 shares 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |